Marketing-authorisation holder · Ireland
Amgen Technology (Ireland) UC
14 medicines in 4 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Ireland
14 medicines in 4 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
14 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Bekemv | Eculizumab | EU (EMA) | Authorised | 2023 |
| Mvasi | Bevacizumab | EU (EMA) | Authorised | 2018 |
| Pavblu | Aflibercept | EU (EMA) | Authorised | |
| PAVBLU 40 mg/ml oplossing voor injectie in een injectieflaconOplossing voor injectie | Aflibercept | Netherlands | Authorised | 2025 |
| PAVBLU 40 mg/ml oplossing voor injectie in voorgevulde spuitOplossing voor injectie | Aflibercept | Netherlands | Authorised | 2025 |
| Wezenla | Ustekinumab | EU (EMA) | Authorised | 2024 |
| WEZENLASoluzione iniettabile in penna pre-riempita | Ustekinumab | Italy | Authorised | |
| WEZENLA 130 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Ustekinumab | Netherlands | Authorised | 2024 |
| WEZENLA 45 mg oplossing voor injectieOplossing voor injectie | Ustekinumab | Netherlands | Authorised | 2024 |
| WEZENLA 45 mg oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Ustekinumab | Netherlands | Authorised | 2024 |
| WEZENLA 90 mg oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Ustekinumab | Netherlands | Authorised | 2024 |
| MVASI 25mg/ml25mg/ml · Conc. pt. sol. perf. | Bevacizumab | Romania | unknown | |
| Skojoy | Aflibercept | EU (EMA) | Refused | |
| Upstelda | Ustekinumab | EU (EMA) | Refused |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| European Union (EMA) | 6 | 4 | 2 | CompaniesAll medicines |
| Netherlands | 6 | 6 | 0 | CompaniesAll medicines |
| Italy | 1 | 1 | 0 | CompaniesAll medicines |
| Romania | 1 | 0 | 1 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.